GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims ...

该诉讼声称，Moderna用于将mRNA传递到细胞中的脂质纳米粒子侵犯了GSK的专利。根据GSK的说法，这些专利是Moderna疫苗产品所使用的mRNA技术的基础。GSK此前曾在同一法院对辉瑞制药公司和BioNTech提起类似诉讼，针对的是他们联合开发的COVID-19疫苗。

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years. The US ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK said that its urinary tract infections treatment gepotidacin has been accepted for priority review by the U.S.'s Food and Drug Administration.

Hindustan Unilever Limited (HUL) has filed an appeal with the Commissioner of Income Tax, challenging a tax demand of Rs 962 ...